BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 27268090)

  • 1. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.
    Bolzoni M; Chiu M; Accardi F; Vescovini R; Airoldi I; Storti P; Todoerti K; Agnelli L; Missale G; Andreoli R; Bianchi MG; Allegri M; Barilli A; Nicolini F; Cavalli A; Costa F; Marchica V; Toscani D; Mancini C; Martella E; Dall'Asta V; Donofrio G; Aversa F; Bussolati O; Giuliani N
    Blood; 2016 Aug; 128(5):667-79. PubMed ID: 27268090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
    Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
    J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pro-proliferative effect of interferon-γ in breast cancer cell lines is dependent on stimulation of ASCT2-mediated glutamine cellular uptake.
    Silva C; Andrade N; Rodrigues I; Ferreira AC; Soares ML; Martel F
    Life Sci; 2021 Dec; 286():120054. PubMed ID: 34662550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
    Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
    Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.
    Tardito S; Chiu M; Uggeri J; Zerbini A; Da Ros F; Dall'Asta V; Missale G; Bussolati O
    Curr Cancer Drug Targets; 2011 Oct; 11(8):929-43. PubMed ID: 21834755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
    Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
    J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer therapeutic potential of glutamine depletion based on GS expression.
    Furusawa A; Miyamoto M; Takano M; Tsuda H; Song YS; Aoki D; Miyasaka N; Inazawa J; Inoue J
    Carcinogenesis; 2018 May; 39(6):758-766. PubMed ID: 29617730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
    Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
    Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin upregulates glutamine transport in human intestinal epithelial cells: the protective mechanism of glutamine on intestinal mucosa after chemotherapy.
    Nose S; Wasa M; Tazuke Y; Owari M; Fukuzawa M
    JPEN J Parenter Enteral Nutr; 2010; 34(5):530-7. PubMed ID: 20852181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes.
    Gegelashvili M; Rodriguez-Kern A; Pirozhkova I; Zhang J; Sung L; Gegelashvili G
    Neurochem Int; 2006; 48(6-7):611-5. PubMed ID: 16516348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
    Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luminal leptin inhibits L-glutamine transport in rat small intestine: involvement of ASCT2 and B0AT1.
    Ducroc R; Sakar Y; Fanjul C; Barber A; Bado A; Lostao MP
    Am J Physiol Gastrointest Liver Physiol; 2010 Jul; 299(1):G179-85. PubMed ID: 20448142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligodendroglioma Cells Lack Glutamine Synthetase and Are Auxotrophic for Glutamine, but Do not Depend on Glutamine Anaplerosis for Growth.
    Chiu M; Taurino G; Bianchi MG; Ottaviani L; Andreoli R; Ciociola T; Lagrasta CAM; Tardito S; Bussolati O
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
    Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
    Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
    Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
    J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamine transport in C6 glioma cells: substrate specificity and modulation in a glutamine deprived culture medium.
    Dolińska M; Dybel A; Hilgier W; Zielińska M; Zabłocka B; Buzańska L; Albrecht J
    J Neurosci Res; 2001 Dec; 66(5):959-66. PubMed ID: 11746424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of glutamine metabolism by the tumor suppressor Rb.
    Reynolds MR; Lane AN; Robertson B; Kemp S; Liu Y; Hill BG; Dean DC; Clem BF
    Oncogene; 2014 Jan; 33(5):556-66. PubMed ID: 23353822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
    Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
    J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
    Bröer A; Rahimi F; Bröer S
    J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.